Note: This document contains side effect information about evinacumab. Some dosage forms listed on this page may not apply to the brand name Evkeeza.
Applies to evinacumab: intravenous solution.
Serious side effects of Evkeeza
Along with its needed effects, evinacumab (the active ingredient contained in Evkeeza) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking evinacumab:
Less common
- Chest tightness
- cough
- difficulty swallowing
- dizziness
- fast heartbeat
- hives, itching, skin rash
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- trouble breathing
- unusual tiredness or weakness
Other side effects of Evkeeza
Some side effects of evinacumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Chills
- diarrhea
- fever
- general feeling of discomfort or illness
- headache
- itching at the injection site
- joint pain
- loss of appetite
- muscle aches, pains, or weakness
- nausea
- shivering
- sore throat
- stuffy or runny nose
- sweating
- trouble sleeping
- vomiting
Less common
- Body aches or pain
- constipation
- ear congestion
- lack or loss of strength
- loss of voice
- pain in the arms or legs
- sneezing
- stomach pain
For Healthcare Professionals
Applies to evinacumab: intravenous solution.
General
The more frequently reported adverse reactions have included nasopharyngitis, influenza-like illness, dizziness, rhinorrhea, and nausea.[Ref]
Hypersensitivity
Anaphylaxis was reported in 1 patient receiving this drug during clinical trials and led to discontinuation of treatment.
Uncommon (0.1% to 1%): Anaphylaxis
Respiratory
Compared to placebo, upper respiratory tract infection and nasal congestion were reported at a higher incidence; incidence was less than 3% of patients.
Very common (10% or more): Nasopharyngitis (16%)
Common (1% to 10%): Rhinorrhea
Frequency not reported: Upper respiratory tract infection, nasal congestion
Immunologic
Frequency not reported: Influenza-like illness
Compared to placebo, influenza-like illness was reported at a higher incidence; incidence was less than 3% of patients.
Cardiovascular
During clinical trials, transient decreases in diastolic blood pressure and increases in heart rate occurred but did not require intervention and resolved post infusion.
Frequency not reported: Diastolic blood pressure decreased, increased heart rate
Nervous system
Common (1% to 10%): Dizziness
Gastrointestinal
Compared to placebo, constipation and abdominal pain were reported at a higher incidence; incidence was less than 3% of patients.
Common (1% to 10%): Nausea
Frequency not reported: Constipation, abdominal pain
Musculoskeletal
Common (1% to 10%): Extremity pain
Other
Common (1% to 10%): Asthenia
Local
Infusion site reactions including infusion site pruritus, pyrexia, muscular weakness, nausea, and nasal congestion were reported in 7% of patients (n=6) receiving this drug compared to 4% (n=2) of placebo patients.
Common (1% to 10%): Infusion site reactions
